Wound Sealant
Project Number:
Patent Number:
The technology was developed by Dr. Douglas R. Miller, former research scientist in animal science, and Dr. Ian R. Tizard, professor of veterinary pathobiology in The Texas A&M University System (TAMU).

A collagen-based wound sealant, prepared as a thick liquid and poured or injected into a wound, where it polymerizes in situ. Suitable for human medical, veterinary, and dental practice applications, the sealant could improve the success rate of healing difficult wounds such as bedsores and diabetic ulcers. The TAMU sealant has been shown to speed the closure of wounds and increase the incidence of healing in preliminary tests with laboratory animals. The sealant could also potentially serve as a drug delivery system with broad applications for human medical, veterinary, and dental practice applications.

Minor wounds normally heal with minimal treatment, but more serious injuries, wounds that recur or wounds complicated by other factors such as age or diabetes often require assistance to heal. Healing of such wounds is often further complicated by infection and is conventionally achieved primarily by encouraging scar tissue formation. The TAMU sealant is gentle but strong, and could increase the over-all healing success rate for recurrent wounds such as pressure ulcers, which are typically treated repeatedly with no permanent solution.

The wound sealant is in liquid form and is easy to apply either by pouring or injection. Collagen, which naturally comprises 60% of skin, gives mechanical strength to the wound. The technique uses a cross-linking reaction to bind the collagen to the wound, where it forms a semi-solid gel that does not need to be removed.

Growth factors can increase the incidence of healing. The substances that stimulate new tissue growth usually only last a few seconds before enzymes in the body break them down. The fibroblast growth factor stimulates the growth of fibroblasts and epithelial cells, and also stimulates angiogenesis, which is the in-growth of new blood vessels. The TAMU wound sealant will allow the fibroblast growth factor which is incorporated into the sealant, to persist longer. It should also work with other growth factors.

The incidence of infection could also be reduced due to antibiotics in the sealant. The compounds used have natural antibiotic properties, and additional time-released antibiotics can be incorporated. Another additive to the sealant helps with scarring. Similarly, topical anesthetics or other time-released drugs could be added, creating a wide range of potential medical, dental and veterinary applications.

  • Ease of application
  • Polymerization of the sealant takes effect in situ
  • Mechanical strength and elasticity
  • Cellular compatibility and faster healing
  • Relatively low-cost materials
  • Base material components may be modified for alternative applications
The patented technology has potential applications for soft tissue wound repair and may be used alone or in conjunction with other products throughout veterinary medical, human medical and dental practice. Alternative use is as a drug delivery system, which might include a slow release depot for vaccines, adjuvants or drugs, bone repair, or graft or prosthetic implant stabilization. The base material can be modified by inclusion of other matrix components, co-reactants, non-reactive materials, growth factors, antibiotics and microbeads (e.g., delayed-release biodegradable beads).
Potential commercial licenses for this technology are participants in medical devices, biotechnology and tissue engineering companies.

For more information please contact:

Conrad F. Mir
President, CEO and Director
Calmare Therapeutics Incorporated
This email address is protected. Javascript must be enabled to view it.
Tel: 203.712.7893